Hillsdale Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,760
| Closed | -$656K | – | 656 |
|
|
2024
Q1 | $656K | Sell |
4,760
-50
| -1% | -$6.9K | 0.05% | 249 |
|
|
2023
Q4 | $634K | Buy |
+4,810
| New | +$634K | 0.05% | 235 |
|
|
2023
Q3 | – | Sell |
-4,340
| Closed | -$409K | – | 621 |
|
|
2023
Q2 | $409K | Hold |
4,340
| – | – | 0.04% | 288 |
|
|
2023
Q1 | $439K | Buy |
4,340
+400
| +10% | +$40.5K | 0.04% | 344 |
|
|
2022
Q4 | $471K | Buy |
3,940
+3,800
| +2,714% | +$454K | 0.04% | 362 |
|
|
2022
Q3 | $15K | Hold |
140
| – | – | ﹤0.01% | 488 |
|
|
2022
Q2 | $14K | Buy |
+140
| New | +$14K | ﹤0.01% | 483 |
|
|
2013
Q4 | – | Sell |
-3,900
| Closed | -$44K | – | 568 |
|
|
2013
Q3 | $44K | Buy |
+3,900
| New | +$44K | 0.01% | 422 |
|